Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected as documented by positive HIV antibody test and confirmed by Western Blot.~* Subject is in need for a switch in maintenance regimen due to adverse effects, toxicities, simplification and/or resistance.~* Subject is at least 18 years of age at the day of screening.~* Subject is able and willing to sign the Informed Consent Form prior to screening evaluations.~* HIV-1 RNA \< 40 copies/mL for at least 6 months on antiretroviral therapy prior to inclusion.~* Subject has no documented resistance mutations to PIs, INSTIs or lamivudine.~Exclusion Criteria:~* Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.~* Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion.~* Inability to understand the nature and extent of the trial and the procedures required.~* Pregnant female (as confirmed by an HCG test performed less than 3 weeks before the first dose) or breast-feeding female.~* Abnormal serum transaminases determined as levels being \> 5 times upper limit of normal.~* Renal failure determined as an estimated Glomerular Filtration Rate (eGFR) \< 50 ml/min (MDRD-based).~* Concomitant use of medications that interfere with atazanavir, dolutegravir or lamivudine pharmacokinetics: oxcarbazepine, phenytoin, phenobarbital, carbamazepine, St. John's wort, rifampicin, clarithromycin, H2 receptor antagonists, proton pump inhibitors, irinotecan, midazolam, triazolam, buprenorphine, aprepitant, modafinil, imatinib, co-trimoxazole, other antiretroviral drugs.~* Concomitant use of medications that are contraindicated for use with atazanavir, dolutegravir or lamivudine: alfuzosin, dofetilide, pimozide, quetiapine, quinidine, bepridil, simvastatin, atorvastatin, lovastatin, sildenafil (as for use in pulmonary arterial hypertension), cladribine.~* Active hepatobiliary or hepatic disease (including chronic hepatitis B or C infection).~* Alcohol abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRADAII regimen (Type: EXPERIMENTAL): Use of PRADAII regimen during 12 weeks. This regimen consists of atazanavir 400 mg QD, dolutegravir 50 mg QD, lamivudine 300 mg QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).